ArticleInvestigative radiology2026
Gadopiclenol Breast MRI With Half Standard Gadolinium Dose Maintains High Parenchymal Contrast in Intraindividual Comparison.
Article in Investigative radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the contrast enhancement of the breast parenchyma in MRI using gadopiclenol (GP) at half the standard dose of gadolinium compared with gadobutrol (GB) at the standard dose of gadolinium. MATERIALS AND
methodsThis retrospective, single-center study considered 319 consecutive female patients who underwent breast MRI with a half-standard dose of gadopiclenol (0.05 mmol/kg) between January and March of 2025. Complete data sets of patients who had received a prior cycle-appropriate MRI using a standard dose of gadobutrol (0.1 mmol/kg) within 2 years, without interim therapy, were evaluated. Absolute signal enhancement of the aorta, axillary lymph nodes, and breast parenchyma was measured to provide an objective assessment. Two independent radiologists evaluated subjective image quality and diagnostic confidence using a 5-point Likert Scale in a side-by-side comparison. Statistical analyses were performed using Wilcoxon signed-rank tests and weighted Cohen kappa.
resultsA total of 145 patients (mostly with hereditary breast and ovarian cancer syndrome) met the inclusion criteria. GP revealed significantly higher absolute enhancement values for all regions (eg, breast parenchyma: GP: 41.8, IQR: 27.1 to 65.4 vs GB: 33.4, IQR: 21.6 to 56.3; P < 0.001). Both contrast agents achieved excellent overall diagnostic confidence ratings (5; IQR: 4 to 5) and demonstrated moderate agreement (GP: κ = 0.59/ GB: κ = 0.48). GP received more excellent ratings (71.9% vs 56.8%; P = 0.002). Most pairs were considered equal on terms of image quality (R1: 90/145; R2: 92/145; P = 0.845) with fair agreement (κ = 0.366). Agreement was achieved in 97 of the 145 cases (67 "equal," 21 "pro GP", and 9 "pro GB"). The combination "equal & pro GP" accounted for most of the remaining comparisons (37/48).
conclusionBreast MRI using gadopiclenol with half standard gadolinium dose offers equivalent to superior objective contrast enhancement and subjective diagnostic confidence compared with a gadobutrol-enhanced MRI with full standard gadolinium dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.